Traws Pharma, Inc.
- Jurisdiction
United States - LEI
549300BRAR7BTG2PIY51 - ISIN
US68232V8845 (TRAW )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
0
/ 7
Profile
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. Read full profile
Stock price
Fundamentals
- Net revenue
€2.48M - Gross margin
99.9% - EBIT
-€17.29M - EBIT margin
-698.1% - Net income
-€15.20M - Net margin
-613.9%
Statement period: - (published )
Dividends
No dividend payouts